[{"from": "human", "value": "Could you provide a description of this molecule? [C][N][C][=C][Branch2][Ring1][C][C][=C][Ring1][Branch1][C][=Branch1][C][=O][N][C][C][N][=C][Branch1][C][N][N][N][C][=Branch1][C][=O][C][=C][C][=Branch1][=Branch1][=C][N][Ring1][Branch1][C][N][C][=Branch1][C][=O][C][=C][C][=Branch1][=Branch1][=C][N][Ring1][Branch1][C][N][C][=Branch1][C][=O][C][=C][C][=Branch1][=Branch1][=C][N][Ring1][Branch1][C][N][C][=Branch1][C][=O][C][=Branch1][C][=C][Br]"}, {"from": "gpt", "value": "The molecule is a synthetic, alpha-bromoacrylic, second-generation minor groove binder (MGB), related to distamycin A, with potential antineoplastic activity. Brostallicin binds to DNA minor groove DNA, after having formed a highly reactive glutathione (GSH)-brostallicin complex in the presence of the enzyme glutathione S-transferase (GST), which is overexpressed in cancer cells; DNA replication and cell division are inhibited, resulting in tumor cell death. Compared to typical MGBs, this agent appears to bind covalently to DNA in a different manner and its activity does not depend on a functional DNA mismatch repair (MMR) mechanism. Accordingly, brostallicin may be effective against MMR-defective tumors that are refractory to various anticancer agents."}]